Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis”In the company’s words, NCT06137157 on ClinicalTrials.gov
- Tested for
- Netherton Syndrome
- Main trialPhase 1
- “The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.”In the company’s words, NCT06137157 on ClinicalTrials.gov
- Other names
- ATR-12
Other drugs for Netherton Syndrome
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 7 Jul 2026 | Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026